Evidence mapPaperPMID 39030553Full record

ArticleNutrition & metabolism2024

Impact of very low carbohydrate ketogenic diets on cardiovascular risk factors among patients with type 2 diabetes; GRADE-assessed systematic review and meta-analysis of clinical trials.

Parisa Ghasemi, Malihe Jafari, Saber Jafari Maskouni, Seyed Ahmad Hosseini, Roksaneh Amiri, Jalal Hejazi, Mahla Chambari, Ronia Tavasolian, Mehran Rahimlou

Registry-linked trialAbstract read
In one paragraph

Article in Nutrition & metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07452913 (Comparative Efficacy and Safety of Metformin-Empagliflozin-Sitagliptin vs. Metformin-Empagliflozin-Linagliptin as Initial Triple Therapy in Type 2 Diabetes Mellitus), which is not on this map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07452913 phase4enrolling by invitationstarted 2026, after this paper: background citation

Comparative Efficacy and Safety of Metformin-Empagliflozin-Sitagliptin vs. Metformin-Empagliflozin-Linagliptin as Initial Triple Therapy in Type 2 Diabetes Mellitus

Ran2026Enrolled110Registered outcomes5Posted comparisons0ConditionsType 2 Diabetes MellitusArmsMetformin + Empagliflozin + Linagliptin, Metformin+ Empagliflozin + Sitagliptin
Open the trial in the graph
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Parisa GhasemiResearch Committee, Medical School, Arak University of Medical Sciences, Arak, Iran.
Malihe JafariDepartment of Exercise physiology, Faculty of Physical Education and Sports Sciences, Allameh Tabataba'i University, Tehran, Iran.
Saber Jafari MaskouniDepartment of nutrition, School of Public health, Jiroft University of Medical Sciences, Jiroft, Iran.
Seyed Ahmad HosseiniDepartment of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Roksaneh AmiriMofid Childrens Hospital Clinical Research Development Unit, Shahid Beheshti University of Medical Science, Tehran, Iran.
Jalal HejaziDepartment of Nutrition, School of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran.
Mahla ChambariDepartment of Food Science and Nutrition, Faculty of Applied Sciences, UCSI University, 56000 Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia.
Ronia TavasolianDepartment of Nutrition, School of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran.
Mehran RahimlouDepartment of Nutrition, School of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran. Rahimlum@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study was designed to evaluate the impact of VLCKD on cardiovascular risk factors in patients with T2DM.

methodsUntil March 2024, extensive searches were conducted on PubMed, Scopus, Web of Science, Embase, and other relevant databases. The purpose was to identify clinical trials examining the impact of VLCKD on glycemic control, lipid profile, and blood pressure. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) method was used to assess the evidence's degree of certainty.

resultsOur initial search found a total of 2568 records and finally 29 trials were included in final analysis. Our results showed that adherence from VLCKD led to significant reduction in fasting blood sugar (WMD= -11.68 mg/dl; 95% CI: -18.79, -4.56; P = 0.001), HbA1c (WMD= -0.29; 95% CI: -0.44, -0.14; P < 0.001), HOMA-IR(WMD= -0.71; 95% CI: -1.14, -0.29; P = 0.001), insulin (WMD= -1.45; 95% CI: -2.54, -0.36; P = 0.009), triglyceride (WMD= -17.95; 95% CI: -26.82, -9.07; P < 0.001), systolic blood pressure (WMD= -2.85, 95% CI: -4.99, -0.71; P = 0.009) and diastolic blood pressure (WMD= -1.40; 95% CI: -2.66, -0.13; P = 0.03). We also found a significant increase in high-density lipoprotein (HDL) level after adherence from VLCKD diet (WMD = 3.93, 95% CI: 2.03, 5.84; P = 0.000). We couldn't find any significant differences between groups in term of LDL and total cholesterol levels.

conclusionPeople following a VLCKD experience a more significant improvement in cardiovascular risk factors when compared to individuals on control diets.

Indexed as

T2DM, Meta-analysisType 2 diabetesVery low carbohydrate ketogenic diets

Identifiers

PMID39030553
PMCPMC11264514

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.